Fulvestrant as First-Line Treatment for Advanced Breast Cancer

December 12, 2014
John F. R. Robertson, MD

John F. R. Robertson, MD, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

Clinical Pearls

John F. R. Robertson, MD, professor of surgery, faculty of medicine & health sciences, The University of Nottingham, United Kingdom, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

  • 20-25 years ago, the average survival among patients with advanced breast cancer was 24 months. Now, it is 54.1 months.
  • Overall survival was 5.7 months higher with fulvestrant compared with anastrozole.
  • Benefit for fulvestrant over anastrozole was consistent across subgroups.

<<<

Go back to the SABCS conference page